Despite advances in cardiovascular biology and medical therapy, heart disorders are the leading cause of death worldwide. Cell-based regenerative therapies become a promising treatment for patients affected by heart failure, but also underline the need for reproducible results in preclinical and clinical studies for safety and efficacy. Enthusiasm has been tempered by poor engraftment, survival and differentiation of the injected adult stem cells. The crucial challenge is identification and selection of the most suitable stem cell type for cardiac regenerative medicine. Human pluripotent stem cells (PSCs) have emerged as attractive cell source to obtain cardiomyocytes (CMs), with potential applications, including drug discovery and toxicity screening, disease modelling and innovative cell therapies. Lessons from embryology offered important insights into the development of stem cell-derived CMs. However, the generation of a CM population, uniform in cardiac subtype, adult maturation and functional properties, is highly recommended. Moreover, hurdles regarding tumorigenesis, graft cell death, immune rejection and arrhythmogenesis need to be overcome in clinical practice. Here we highlight the recent progression in PSC technologies for the regeneration of injured heart. We review novel strategies that might overcome current obstacles in heart regenerative medicine, aiming at improving cell survival and functional integration after cell transplantation.

Stem cell technology in cardiac regeneration: a pluripotent stem cell promise / Duelen, Robin; Sampaolesi, Maurilio. - In: EBIOMEDICINE. - ISSN 2352-3964. - 16:(2017), pp. 30-40. [10.1016/j.ebiom.2017.01.029]

Stem cell technology in cardiac regeneration: a pluripotent stem cell promise

SAMPAOLESI, MAURILIO
2017

Abstract

Despite advances in cardiovascular biology and medical therapy, heart disorders are the leading cause of death worldwide. Cell-based regenerative therapies become a promising treatment for patients affected by heart failure, but also underline the need for reproducible results in preclinical and clinical studies for safety and efficacy. Enthusiasm has been tempered by poor engraftment, survival and differentiation of the injected adult stem cells. The crucial challenge is identification and selection of the most suitable stem cell type for cardiac regenerative medicine. Human pluripotent stem cells (PSCs) have emerged as attractive cell source to obtain cardiomyocytes (CMs), with potential applications, including drug discovery and toxicity screening, disease modelling and innovative cell therapies. Lessons from embryology offered important insights into the development of stem cell-derived CMs. However, the generation of a CM population, uniform in cardiac subtype, adult maturation and functional properties, is highly recommended. Moreover, hurdles regarding tumorigenesis, graft cell death, immune rejection and arrhythmogenesis need to be overcome in clinical practice. Here we highlight the recent progression in PSC technologies for the regeneration of injured heart. We review novel strategies that might overcome current obstacles in heart regenerative medicine, aiming at improving cell survival and functional integration after cell transplantation.
2017
embryonic cardiomyogenesis; heart regeneration; human pluripotent stem cell; stem cell-based therapy; stem cell-derived exosome; animals; heart failure; humans; models; biological; myocytes; cardiac; pluripotent stem cells; regeneration; regenerative medicine; treatment outcome; cell differentiation; medicine (all); biochemistry; genetics and molecular biology (all)
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Stem cell technology in cardiac regeneration: a pluripotent stem cell promise / Duelen, Robin; Sampaolesi, Maurilio. - In: EBIOMEDICINE. - ISSN 2352-3964. - 16:(2017), pp. 30-40. [10.1016/j.ebiom.2017.01.029]
File allegati a questo prodotto
File Dimensione Formato  
Duelen_Stem-cell_2017.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 731.34 kB
Formato Adobe PDF
731.34 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1581720
Citazioni
  • ???jsp.display-item.citation.pmc??? 36
  • Scopus 78
  • ???jsp.display-item.citation.isi??? 68
social impact